FEDERAL COURT OF AUSTRALIA
Industrial Galvanizers Corporation Pty Ltd v Safe Direction Pty Ltd [2018] FCA 1192
File number: NSD 600 of 2016 Judge: BURLEY J Date of judgment: 10 August 2018 Catchwords: PATENTS – priority date – external fair basis – whether patent date deferred by subsequent amendment – held no real and reasonably clear disclosure in unamended specification of what was claimed as a result of the amendment
PATENTS – internal fair basis – whether claimed invention is fairly based on disclosure in the specification – held claims of Final patent fairly based on the specification
PATENTS – personal liability of director for infringement by company – joint tortfeasor – meaning of “authorise” under s 13 of the Patents Act – held no joint tortfeasorship or authorisation
CONSUMER LAW – misleading or deceptive conduct in contravention of the Australian Consumer Law – whether offer for sale, sale, distribution, advertisement, supply, exhibition and promotion of product constitutes a representation in trade or commerce that the purchaser will have a right to use the product – held no contravention of the Australian Consumer Law
Legislation: Competition and Consumer Act 2010 (Cth), Schedule 2, s 18
Copyright Act 1958 (Cth)
Intellectual Property laws Amendment (Raising the Bar) Act 2012 (Cth), Schedule 1, part 3, cl 55
Patents Act 1990 (Cth), ss 13, 40, 43, 114, 122
Patents Regulations 1991 (Cth), reg 3.14
Cases cited: Adelaide Corporation v Australasian Performing Right Association Ltd [1928] HCA 10; (1928) 40 CLR 481
Advanced Building Systems Pty Ltd v Ramset Fasteners (Aust) Pty Ltd & Ors [1995] FCA 236; (1995) AIPC 91-129
Allen Manufacturing Co Pty Ltd v McCallum & Co Pty Ltd [2001] FCA 1838; (2001) 53 IPR 400
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; (2014) 226 FCR 324
Australian Securities and Investments Commission v Fortescue Metals Group Ltd [2011] FCAFC 19; (2011) 190 FCR 364
Bristol-Myers Squibb v FH Faulding [2000] FCA 316; (2000) 97 FCR 524
Cooper v Universal Music Australia Pty Ltd [2006] FCAFC 187; (2006) 156 FCR 380
Heydon v NRMA Ltd [2000] HCA 374; (2000) 51 NSWLR 1
Inverness Medical Switzerland GMBH v MDS Diagnostics Pty Ltd [2010] FCA; (2010) 85 IPR 525
JR Consulting & Drafting Pty Ltd v Cummings [2016] FCAFC 20; 116 IPR 440
Jupiters Ltd v Neurizon Pty Ltd [2005] FCAFC 90; (2005) 65 IPR 86 at [67]
Keller v LED Technologies Pty Ltd [2010] FCAFC 55; (2010) 185 FCR 449
Kimberly-Clark Australia v Arico Trading [1998] FCA 1103; (1998) 42 IPR 111
Lockwood Security ProductsPty Ltd v Doric Products Pty Ltd [2004] HCA 58; (2004) 217 CLR 274
Mentmore Manufacturing Co Ltd v National Merchandising Manufacturing Co Inc (1978) 89 DLR (3d) 195
Microsoft Corporation v Auschina Polaris Pty Ltd [1996] FCA 1069; (1996) 71 FCR 231
Performing Right Society Ltd v Ciryl Theatrical Syndicate Ltd [1924] 1 KB 1
Keep reading for free
Create a free CaseChat account to read Industrial Galvanizers Corporation Pty Ltd v Safe Direction... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] FCA 1192
- Decision Date
CaseChat Overview and Summary
The court found that the claims of the Final Patent lacked novelty due to the Safe Direction Patent, indicating that the invention disclosed in the Complete Patent was sufficiently clear and complete. However, the court upheld the validity of the Final Patent, concluding that the claims were fairly based on the specification despite the absence of the axial alignment feature in the Complete Patent. The court also ruled that Mr Wallace was not liable as a joint tortfeasor or as someone who authorised Safe Direction's infringement of the patent. Furthermore, the court held that Safe Direction was not liable for additional damages and did not contravene s 18 of the ACL by implying consumers would have rights to use the patented product.
The court's reasoning was grounded in the detailed examination of patent law principles, particularly the requirements for novelty and fair basis, as well as the interpretation of statutory provisions regarding authorisation and joint tortfeasorship under the Patents Act. The findings on the ACL claim were based on the interpretation of consumer protection laws and the specific representations made by Safe Direction regarding the use of their product. The court's decision was comprehensive, addressing each of the issues raised by the parties with careful consideration of the evidence and legal arguments presented.
Orders
Orders of the court
(1) Pursuant to s 37AF of the Federal Court of Australia Act 1976 (Cth), until further order, these reasons:
(a) will be disclosed to the following persons only:
(i) any judge, employee or other personnel of this Court;
(ii) the First Respondents, including its employees, directors, shareholders and external legal representatives;
(iii) the Second Respondent and its external legal representatives;
(iv) external legal representatives of the Applicant who have signed a confidentiality undertaking in the form agreed between the Second Respondent and the Applicant; and
(v) such other persons authorised by the First or Second Respondents or as the Court may order;
(b) will not be open to public inspection or disclosed in open Court or disclosed in the open part of any Court transcript.
(2) Within 7 days of the date of this judgment, after conferring, the parties inform my chambers where, if at all, it is claimed that the reasons for judgment contain information in respect of which a non-publication order has been or should be made.
(3) Within 14 days of the date of this judgment, the parties endeavour to agree as to the appropriate form of orders (including as to costs) to be made reflecting the conclusions expressed in these reasons.
(4) In the event that no agreement is reached, within 21 days of the date of this judgment, the parties are to notify the Court as to the orders for which they contend (in mark-up) and supply written submissions of no more than 5 pages in length addressing their respective contentions and indicating whether they desire to be heard on the issues addressed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
The matter was heard in the Federal Court of Australia. Prior to this hearing, Ingal and Safe Direction had engaged in several rounds of pleadings, including statements of claim, defences, and further amended statements of claim. Various expert witnesses were involved in the proceedings, providing affidavits and participating in expert reports concerning the technical aspects of the patent claims. Safe Direction filed motions seeking to strike out certain parts of Ingal's claims, which were considered during the hearing. The court had to determine several key issues, including the validity of the patent, the liability of the director, and potential ACL breaches.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Ingal submits that the evidence of Dr Plaxico is consistent with that of Professor Grzebieta.2.5 Consideration of external fair basis In considering the matter disclosed in the Complete Patent, one must have regard to the entirety of the disclosure of that document as it would be understood by the person skilled in the art armed with the common general knowledge as at the relevant priority date. There was no dispute between the parties that both of the experts were suitably qualified, or that they approached their task in light of the relevant common general knowledge as at the relevant date. The experts explain that the invention described in the Complete Patent is directed towards an improved post which assists the guard rail in better performing its function during a collision by allowing the guard rail to remain in place during a collision. This is done through the post being frangible or collapsible in a controlled manner as described in the specification. That is, the post releases the guard rail at an appropriate moment so as to facilitate redirection of the errant vehicle away from the hazard. For present purposes the essential question is whether the Complete Patent made a real and reasonably clear disclosure of what was claimed as a result of the amendments; AstraZeneca at [242]. This involves first considering claim 1 of the Final Patent and then comparing that with the matter disclosed in the Complete Patent. Claim 1 of the Final Patent is set out in [39] above. It is for a post and guard assembly consisting of a post that includes an elongated mounting hole for connecting the guard rail to the post using a bolt passing through the guard rail and the mounting hole, the mounting hole being located below the upper edge of the post and including one or more apertures or slots spaced from the mounting hole wherein one of the apertures or slots has a perimeter or perimeter length longer than that of the mounting hole. There is no dispute that the axial alignment feature is absent from this claim (and all other claims of the Final Patent, which are dependent on claim 1). The debate between the parties accordingly focusses attention on whether a combination that includes the limitations contained in that feature was in substance disclosed in the Complete Patent. In my view the disclosure of the Complete Patent is of a post for a guard rail system and a guard rail assembly that consists of a number of features and which includes a limitation that the apertures or slots be located above the mounting hole and that they by axially aligned with a central longitudinal axis of the mounting hole (that is, the axial alignment feature). The apparent purpose of the particular alignment of the apertures or slots is, as Dr Plaxico said, to create a pathway for the bolt and the lands between these slots which are meant to create resistance by impeding the bolt’s upward movement through the slots. In reaching this view I have regard to the whole of the disclosure of the Complete Patent.